Merck Looks To Leverage "Next 10" For Growth: Emerging Markets Earnings Roundup (Part 4)
This article was originally published in PharmAsia News
Executive Summary
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls. Merck & Co., which aims to see one-fourth of its revenue come from emerging markets by 2013, focused investment in best growth drivers and sales efficiency to bolster key products. Merck's emerging markets strategy will focus on maximizing its own brands, leveraging partnerships with low-cost makers and looking for "inter-brand" opportunities.
You may also be interested in...
Japan Clears Merck's Gardasil To Ease HPV Vaccine Shortage; AstraZeneca, Astellas Also Gain Approvals
July kicks off a good start for the Japanese subsidiary of Merck & Co. Inc., known as Merck, Sharp & Dohme, with three new drug approvals from Japan's Ministry of Health, Labor and Welfare. Among them, cervical cancer vaccine Gardasil will largely benefit from a recently expanded Japanese government public coverage program for human papillomavirus vaccines
Japan Clears Merck's Gardasil To Ease HPV Vaccine Shortage; AstraZeneca, Astellas Also Gain Approvals
July kicks off a good start for the Japanese subsidiary of Merck & Co. Inc., known as Merck, Sharp & Dohme, with three new drug approvals from Japan's Ministry of Health, Labor and Welfare. Among them, cervical cancer vaccine Gardasil will largely benefit from a recently expanded Japanese government public coverage program for human papillomavirus vaccines
Merck Tagged With Non-compliance In Japan For 3,600 Physicians' Unjustified Honoraria
TOKYO - Merck & Co. Inc - known as MSD in Japan - is trying to remediate internal oversight measurers quickly after it received a "strict warning" from an independent compliance council for improper payments to a total of 3,604 physicians in Japan between January 2009 and December 2010, which constituted violations of the Fair Competition Code